Nile Therapeutics Announces Dosing In Second Phase Ib Study Of CD-NP In Heart Failure Patients

Nile Therapeutics, Inc. (Nasdaq: NLTX), announced that Mayo Clinic has initiated a Phase Ib, double-blind, placebo-controlled clinical study of CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure. The primary objective of the study is to assess renal, neurohumoral and non-invasive hemodynamic physiologic parameters of intravenous infusions of CD-NP in patients with heart failure.

More: continued here

Filed under: Cardiovascular on July 31st, 2008